Fusion Toxin

2020 ◽  
Author(s):  
Keyword(s):  
Fusion Toxin

scholarly journals Fusion toxin protein inhibits CMV infection

2015 ◽  
Vol 14 (8) ◽  
pp. 528-528
Author(s):  
Sarah Crunkhorn
Keyword(s):  
Cmv Infection ◽  
Fusion Toxin ◽  
Toxin Protein

Fusion Protein of Interleukin 4 and Diphtherial Toxin with High Cytotoxicity to Cancer Cells

2004 ◽  
Vol 36 (6) ◽  
pp. 437-442
Author(s):  
Yu-Jian Zhang ◽  
Xiao-Bo Hu ◽  
Su-Xia Li ◽  
Li-Ping Tian ◽  
Sheng-Li Yang ◽  
...  
Keyword(s):  
Fusion Gene ◽  
Cancer Cell Line ◽  
Interleukin 4 ◽  
Toxin Gene ◽  
Cytotoxic Action ◽  
Fusion Toxin ◽  
Good Target ◽  
Sequence Encoding ◽  
High Cytotoxicity ◽  
Mcf 7

Abstract Receptor of human interleukin 4 (hIL4R) has been found to be present on many types of cancer, so it may be a good target for cancer therapy. Here, fusion toxin gene DT4H has been constructed by fusing DNA sequence encoding the first 389 amino acids of diphtherial toxin (DT), which can not bind its own receptor, to human interleukin 4 (hIL4) gene. In order to improve the affinity of fusion toxin for hIL4R, a circularly permuted form of hIL4 (cpIL4) was used. The fusion gene was expressed in Escherichia coli where the fusion toxin DT4H was highly expressed. Purified DT4H was very cytotoxic to cancer cell line U251 cells, and moderate cytotoxic to HepG2 and MCF-7 cells. SGC-7901 cells were insensitive to it. The cytotoxic action of DT4H was specific because it was blocked by excess hIL4. These results suggest that DT4H may be a useful agent in the treatment of certain malignancies.

scholarly journals A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin

2013 ◽  
Vol 391 (1-2) ◽  
pp. 103-111 ◽  
Author(s):  
Jaclyn Stromp Peraino ◽  
Marian Schenk ◽  
Huiping Zhang ◽  
Guoying Li ◽  
Christina E. Hermanrud ◽  
...  
Keyword(s):  
Diphtheria Toxin ◽  
Fusion Toxin

scholarly journals Advances in the treatment of cytomegalovirus

2019 ◽  
Vol 131 (1) ◽  
pp. 5-17 ◽  
Author(s):  
B A Krishna ◽  
M R Wills ◽  
J H Sinclair
Keyword(s):  
Immune Responses ◽  
Dna Polymerase ◽  
Hcmv Infection ◽  
Research Papers ◽  
Fusion Toxin ◽  
Latently Infected ◽  
Congenital Hcmv Infection ◽  
Infected Cells ◽  
Toxin Protein ◽  
Published Research

Abstract Background Human cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances. Sources of data Sources of data are recently published research papers and reviews about HCMV treatments. Areas of agreement Current antivirals target the UL54 DNA polymerase and are limited by nephrotoxicity and viral resistance. Promisingly, letermovir targets the HCMV terminase complex and has been recently approved by the FDA and EMA. Areas of controversy Should we screen newborns for HCMV, and use antivirals to treat sensorineural hearing loss after congenital HCMV infection? Growing points Growing points are developing drugs against latently infected cells. In addition to small molecule inhibitors, a chemokine-based fusion toxin protein, F49A-FTP, has shown promise in killing both lytically and latently infected cells. Areas timely for developing research We need to understand what immune responses are required to control HCMV, and how best to raise these immune responses with a vaccine.

scholarly journals Bioactive IL7-diphtheria fusion toxin secreted by mammalian cells

2005 ◽  
Vol 18 (1) ◽  
pp. 25-31 ◽  
Author(s):  
S. Shulga-Morskoy ◽  
B.E. Rich
Keyword(s):  
Mammalian Cells ◽  
Fusion Toxin
Sign in / Sign up

Export Citation Format

Share Document